(Total Views: 599)
Posted On: 09/18/2021 9:00:23 AM
Post# of 153940
Re: Good to go #104466
The IncellDX patent - "Methods of Treating Cytokine Storm Infections, Including COVID-19, by Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same" is only applicable to the drug maraviroc, leronlimab is excluded. Which should make Pfizer mighty unhappy with IncellDX. Maybe Patterson will tell them to buy IncellDX for $350 million.
The second IncellDX patent - "Method Of Treating SARS-CoV-2-Associated Hypercytokinemia By Administering A Human Monoclonal Antibody (Pro-140) That Inhibits Ccr5/Ccl5 Binding Interactions" was found by the Patent Office to be infringing on Cytodyns patent. An appeal has been made by IncellDX and IncellDX's response is due by October 21st. That it specifically indicates leronlimab and Cytodyn's patent already covers leronlimab I don't see the patent office upholding the appeal.
The second IncellDX patent - "Method Of Treating SARS-CoV-2-Associated Hypercytokinemia By Administering A Human Monoclonal Antibody (Pro-140) That Inhibits Ccr5/Ccl5 Binding Interactions" was found by the Patent Office to be infringing on Cytodyns patent. An appeal has been made by IncellDX and IncellDX's response is due by October 21st. That it specifically indicates leronlimab and Cytodyn's patent already covers leronlimab I don't see the patent office upholding the appeal.
(13)
(0)
